Fortrea
Global CRO providing Phase I-IV trials
Manager Recruitment Systems & Processes
+ Company bonus
Must reside in a U.S. Eastern or Central time zone; preferred location is the Raleigh/Durham, North Carolina area.
About the job
- A university degree is preferred.
- At least 7 years of experience providing high-level human resources technology expertise in new product implementations, projects, daily support, and user training.
- Strong human capital management systems experience.
- Background in contingent labor recruitment, management, and processes.
- Strong project management, problem-solving, and analytical skills.
- Strong experience managing human resources technology vendors, suppliers, and agencies, including relationship management, systems integration, contracts, and product support.
- Ability to interact with individuals at all organizational levels.
- Must reside in a United States Eastern or Central time zone.
- Manage and support a variety of Talent Acquisition technology products and processes, including implementations, projects, daily operations, and enhancements or upgrades.
- Partner with senior Human Resources leaders to examine internal technology agreements and support transitions to new technologies.
- Support global contingent labor programs and ensure smooth processing of transitions in Workday.
- Align staffing agencies and suppliers between Workday and global recruiters.
- Partner with Procurement to maintain current agency contracts.
- Support the Workday Human Capital Management platform for global users.
- Manage third-party vendor products, system integrations, and relationships, including LinkedIn, Phenom Customer Relationship Management, and Indeed.
- Design and deliver recruitment technology and process product training to new and existing users.
- Partner with internal customers to understand business objectives and their key drivers.
- Work with cross-functional Human Resources, Information Technology, and Finance teams to ensure seamless product performance across the organization.
- Hands-on Workday user support experience.
About the company
Fortrea is a global contract research organization that provides clinical development services for the life sciences industry. It offers full service, functional service, and hybrid outsourcing models across Phase I–IV trials, clinical pharmacology, and consulting, serving biotech, biopharma, medical devices, and diagnostics. Its work is delivered through a network of investigators and specialized teams in approximately 100 countries, supporting trial design, execution, data management, and regulatory compliance. Fortrea’s approach combines its legacy experience from Covance and Labcorp with a pureplay CRO model to deliver fit-for-purpose solutions and agile project delivery. This positions it to manage trials across more than 20 therapeutic areas with scientific rigor and operational excellence. The company aims to bring predictability to clinical trial execution and help clients turn research ideas into real-world outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
2023
Get referred to Fortrea
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue beat estimates at $678.2 million, lifting full-year guidance.
- Book-to-bill hit 1.06x in Q2, signaling improving demand after biotech recovery.
- Knoblauch returned September 9, 2026, restoring dedicated CFO leadership after litigation.
What critics are saying
- Fortrea's revenue still fell 4.5% in Q2, exposing fragile organic growth.
- FSP headwinds continue, and management cited flat second-half performance after Q2.
- Another CFO lawsuit or compliance dispute shatters buyer trust across Fortrea's pipeline.
What makes Fortrea unique
- Fortrea owns early-phase capabilities after buying Worldwide's CPU and bioanalytical lab in Texas.
- Its 100-country footprint and 20-therapeutic-area depth support global multicenter trials.
- Three decades of clinical development experience gives Fortrea credibility with biopharma sponsors.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 27%1 year growth
↑ 27%2 year growth
↑ 27%Fortrea to participate in September investor conferences. MWN-AI** Summary. Fortrea (Nasdaq: FTRE), a prominent global contract research organization (CRO), has announced its upcoming participation in several key investor conferences in September 2026. Leading this initiative are CEO Anshul Thakral, CFO Jason Knoblauch, and Senior Vice President of Investor Relations Tracy Krumme. The conferences include the Baird 2026 Global Healthcare Conference and Deutsche Bank 2026 Healthcare Summit in New York City, as well as the RBC Pharma Services and Life Science Tools Virtual Conference. On September 15, Fortrea will participate in a fireside chat format at the Baird conference, alongside individual and group meetings, from 2:00 to 2:30 PM EDT. A live webcast of this session will be made available for later access via the Events section of Fortrea's Investor Relations website. The following day, Fortrea will engage in one-on-one and group meetings during the Deutsche Bank summit. Additionally, the company will be involved in similar meeting formats at the RBC virtual conference on September 22. Fortrea stands out as a global leader in providing comprehensive clinical development solutions for the life sciences sector, collaborating with both emerging and established biopharmaceutical, biotechnology, and medical device companies. The organization prides itself on its extensive experience, encompassing over three decades across more than 20 therapeutic areas, and is committed to advancing healthcare innovation that accelerates the delivery of transformative therapies to patients. With a talented workforce of professionals operating in 100 countries, Fortrea is well-equipped to provide agile solutions tailored to global clients. Interested investors and stakeholders can learn more about Fortrea's initiatives and drug development approach by visiting their website and following their updates on social media platforms. MWN-AI** Analysis. As Fortrea (Nasdaq: FTRE) prepares to participate in significant investor conferences throughout September 2026, keen investors should closely monitor the company's developments and performance metrics. With CEO Anshul Thakral and CFO Jason Knoblauch set to engage with investors at the Baird 2026 Global Healthcare Conference and the Deutsche Bank 2026 Healthcare Summit, there's a substantial opportunity for insights into Fortrea's strategic initiatives and operational performance. Fortrea stands out in the contract research organization (CRO) sector, focusing on delivering clinical development solutions to both emerging biopharmaceuticals and established medical firms. The company prides itself on leveraging a rich 30-year history across more than 20 therapeutic areas, indicating robust expertise that investors could view favorably. Additionally, their expansive network of clinical trial sites in over 100 countries ensures comprehensive and agile solutions for clients, positioning Fortrea well amid increasing demand for efficient drug development services. Investors should consider the implications of Fortrea's participation in September conferences for future stock performance. A fireside chat format can often lead to candid communications about the company's pipeline, strategic vision, and market positioning, all of which are key factors influencing investor sentiment. The company's ability to articulate growth prospects and address investor inquiries can potentially lead to increased market confidence. Furthermore, with Fortrea's solutions catering to critical sectors such as biopharmaceuticals and medical devices, the ongoing industry shift towards precision medicine and accelerated drug approvals may provide additional tailwind for Fortrea's growth. Hence, investors might find it prudent to engage with the company's updates and consider investing in FTRE to capitalize on potential upside from upcoming innovations and developments in the healthcare landscape. Engaging with management at these conferences could also yield valuable insights, making outreach critical for investors looking to deepen their understanding of Fortrea's market trajectory. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 10, 2026 08:58:16 am DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) - Fortrea (Nasdaq: FTRE), a leading global contract research organization ("CRO"), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September: Baird 2026 Global Healthcare Conference (NYC) Date: Tuesday, September 15, 2026 Format: Fireside Chat & 1x1 and Group Meetings Time: 2:00 -2:30 PM EDT Webcast: FTRE Baird Webcast Deutsche Bank 2026 Healthcare Summit (NYC) Date: Wednesday, September 16, 2026 Format: 1x1 and Group Meetings RBC Pharma Services and Life Science Tools Virtual Conference Date: Tuesday, September 22, 2026 Format: 1x1 and Group Meetings The live webcast and replay of the Baird fireside chat will be accessible through the "Events" section of Fortrea's Investor Relations website. Investors interested in meeting with management should contact their banking representatives. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. Market Wire News partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Its talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow Market Wire News on LinkedIn, X and Bluesky. Fortrea Contacts Tracy Krumme (Investors) - 984-385-6707, [email protected] Sue Zaranek (Media) - 919-943-5422, [email protected] Kate Dillon (Media) - 646-818-9115, [email protected] FAQ**. What key strategies will Fortrea Holdings Inc. (FTRE) discuss during the Baird 2026 Global Healthcare Conference to showcase their leadership in clinical development solutions? I currently do not have access to specific details about Fortrea Holdings Inc.'s strategies for the Baird 2026 Global Healthcare Conference. Please consult official company announcements or industry news for the latest information. How does Fortrea Holdings Inc. (FTRE) plan to leverage its extensive experience across therapeutic areas during the upcoming Deutsche Bank 20Healthcare Summit? Fortrea Holdings Inc. plans to leverage its extensive experience across therapeutic areas at the Deutsche Bank 2026 Healthcare Summit by showcasing innovative strategies and partnerships that enhance their portfolio and address evolving healthcare needs. What insights does Fortrea Holdings Inc. (FTRE) hope to share with investors at the RBC Pharma Services and Life Science Tools Virtual Conference regarding drug development innovation? Fortrea Holdings Inc. (FTRE) aims to share insights on groundbreaking advancements in drug development and innovative strategies that enhance efficiency and efficacy, positioning their pipeline for growth and competitiveness in the pharmaceutical industry. How is Fortrea Holdings Inc. (FTRE) addressing emerging trends in the biopharmaceutical industry while participating in these September conferences? Fortrea Holdings Inc. (FTRE) is actively engaging at September conferences to showcase its innovative therapies and align with industry trends such as personalized medicine and digital health solutions, highlighting its commitment to advancing biopharmaceutical development. **MWN-AI FAQ is based on asking OpenAI questions about Fortrea Holdings Inc. (NASDAQ: FTRE).
Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division adds a 60,000 sq ft bioanalytical lab. Here's what it means for Phase I site…
Fortrea acquires the clinical pharmacology unit and bioanalytical laboratory activities of Worldwide Clinical Trials. This acquisition brings dedicated bioanalytical expertise and increased capacity to Fortrea's early clinical development network as Worldwide continues its strategy to strengthen its clinical development activities, therapeutic leadership, and presence in high-growth markets.
Fortrea to acquire clinical pharmacology unit and bioanalytical laboratory operations from Worldwide Clinical Trials. September 02, 2026 Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Highlights * Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials * Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas * Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea's ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies * Strengthens Fortrea's end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence generation * Supports Fortrea's growth strategy through expanded scientific capabilities, increased early clinical development capacity and enhanced ability to create long-term value for shareholders * Supports Worldwide Clinical Trials' existing rapid global growth across oncology, neuroscience, internal medicine, and rare disease
Fortrea, a contract research organisation spun off from Labcorp in 2023, reported Q2 revenues of $678.2 million, down 4.5% year-on-year but exceeding analyst expectations by 4.7%. The company helps pharmaceutical, biotech, and medical device companies develop products through clinical trials and support services. Chief executive officer Anshul Thakral said the results reflected continued progress against the company's strategy and disciplined execution. The quarter saw Fortrea beat earnings per share estimates, with full-year revenue guidance surpassing analyst expectations. Among the eight drug development inputs and services stocks tracked, revenues collectively beat consensus estimates by 4.1%. Despite posting the slowest revenue growth in the group, the sector's share prices rose 12.6% on average. Fortrea's stock fell 5.7% following the results and currently trades at $19.52.